J. Kortmansky

发表

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates γ-Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells

M. Gonen, G. Schwartz, C. Jung, 2003 .

Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor.

L. Norton, H. Thaler, N. Onetto, 1995, Journal of the National Cancer Institute.

A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer

J. Lacy, J. Kortmansky, H. Hochster, 2020, Cancer.

Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.

A. Chiang, C. Fuchs, J. Kortmansky, 2018, Journal of oncology practice.

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias

M. Dhodapkar, J. Kortmansky, A. Branagan, 2021, Blood Advances.

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.

A. Zhu, G. Abou-Alfa, R. Kelley, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

R. Salem, J. Lacy, B. Chang, 2016, British Journal of Cancer.

IClinical Trial of the Sequential Combination of Irinotecan Followedby Flavopiridol

C. Cordon-Cardo, M. Gonen, M. Shah, 2005 .

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

M. Gonen, M. Shah, N. Kemeny, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors

M. Shah, G. Schwartz, D. Rathkopf, 2004 .

A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F).

M. Gonen, M. Shah, G. Schwartz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

G. Pond, A. Oza, D. Birle, 2006, British Journal of Cancer.

A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).

J. Lacy, J. Kortmansky, H. Hochster, 2019, Journal of Clinical Oncology.

Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).

R. Salem, J. Lacy, J. Kortmansky, 2015 .

A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).

P. Philip, J. Lacy, A. Shields, 2018 .

Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

G. Schwartz, J. Kortmansky, Gary K Schwartz, 2003, Cancer investigation.

The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.

M. Gonen, G. Schwartz, C. Jung, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

G. Schwartz, L. Saltz, J. Kortmansky, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis

R. Salem, J. Lacy, C. Hallemeier, 2020, Clinical and translational radiation oncology.

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.

P. Philip, J. Lacy, A. Shields, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol

C. Cordon-Cardo, M. Gonen, M. Shah, 2005, Clinical Cancer Research.

Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome

O. Elemento, M. Pittman, P. Philip, 2020, Clinical Cancer Research.

A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer

R. Salem, J. Lacy, J. Kortmansky, 2020, Pancreas.

Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil.

M. Gonen, M. Shah, G. Abou-Alfa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).

R. Salem, J. Lacy, B. Chang, 2014 .

Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma

J. Lacy, J. Kortmansky, H. Hochster, 2017, American journal of clinical oncology.

Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection.

A. Chiang, J. Kortmansky, J. Kanowitz, 2021, Journal of Clinical Oncology.

MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.

J. Desai, N. Segal, M. Fakih, 2019, Journal of Clinical Oncology.

A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer

Gary K. Schwartz, Mithat Gonen, Robert A. Lefkowitz, 2009, Pancreatology.

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Y. Kong, J. Lacy, K. Schalper, 2023, Cancer research communications.

A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer

M. Gonen, M. Shah, G. Schwartz, 2009, Pancreatology.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

G. Pond, A. Oza, D. Birle, 2006, British Journal of Cancer.

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

J. Lacy, J. Kortmansky, S. Boerner, 2023, British journal of cancer.

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update

G. Abou-Alfa, R. Finn, R. Kelley, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.

J. Lacy, M. Muzumdar, J. Kortmansky, 2024, JAMA oncology.

A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer

G. Schwartz, J. Kortmansky, B. Minsky, 2005 .